Inventor · disambiguated record
Jayakumar Sankara Warrier
Also filed as: WARRIER JAYAKUMAR S · WARRIER JAYAKUMAR SANKARA
22 granted patents·8 pending applications·16 citations·filing 2010–2024
91Inventor score
Files withBRISTOL MYERS SQUIBB CO23RIGEL PHARMACEUTICALS INC4HYNES JOHN1JUNO THERAPEUTICS INC1KICK ELLEN K1
Top patents by PatentIndex Score
30 records- 0189US9221796B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Dec 29, 2015·5 cites·12 claims
- 0288US10669272B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 2, 2020·4 cites·13 claims
- 0380US2024400563A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0478US9884868B2TGF-beta inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2016·Granted Feb 6, 2018·2 cites·36 claims
- 0574US2023151007A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 0673US8722670B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2012·Granted May 13, 2014·2 cites·13 claims
- 0771US10344020B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 9, 2019·1 cites·13 claims
- 0868US10954225B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 23, 2021·0 cites·4 claims
- 0967US11713316B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 1, 2023·0 cites·11 claims
- 1066US11584747B2Substituted pyridopyrimidinonyl compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Feb 21, 2023·0 cites·33 claims
- 1166US10336761B2TGFβ receptor antagonistBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 2, 2019·1 cites·6 claims
- 1264US10961229B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 30, 2021·0 cites·12 claims
- 1361US10954238B1Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 23, 2021·0 cites·11 claims
- 1460US8901106B2Imidazole prodrug LXR modulatorsKICK ELLEN K·Filed 2012·Granted Dec 2, 2014·1 cites·14 claims
- 1558US11352360B2TGF-beta inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·0 cites·21 claims
- 1656US12454531B2Substituted piperazine derivatives useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Oct 28, 2025·0 cites·13 claims
- 1756US10501451B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·0 cites·19 claims
- 1855US10287295B2TGF-β inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2018·Granted May 14, 2019·0 cites·20 claims
- 1955US2024108654A1Combination of a t cell therapy and a dgk inhibitorJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2054US11964973B2Substituted bicyclic compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Apr 23, 2024·0 cites·11 claims
- 2154US2023061608A1Substituted quinolinonyl piperazine compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2253US12492172B2Substituted quinazolinyl compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Dec 9, 2025·0 cites·12 claims
- 2352US2023086933A1Substituted heteroaryl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2451US2023089255A1Combinations of dgk inhibitors and checkpoint antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2549US9238666B2Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl] pyridine-3-sulfonamideBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 19, 2016·0 cites·16 claims
- 2649US2013178444A1Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activityBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 2747US8410139B2Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activityHYNES JOHN·Filed 2010·Granted Apr 2, 2013·0 cites·4 claims
- 2843US10961239B2TGF beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 30, 2021·0 cites·11 claims
- 2942US2018250303A1Tgf beta receptor antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 3037US9981944B2GDF-8 inhibitorsRIGEL PHARMACEUTICALS INC·Filed 2016·Granted May 29, 2018·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →